Global Paclitaxel Market to Attain the Value of US$ 160 Mn by 2025 End


 Published Date : 25 Sep 19   |   Views: 165   |  Industry : Life Science

A healthy lifestyle is key to a healthy body. Over the past few years, lifestyle has changed rapidly and attracted many lifestyle related diseases. Cancer is become a very common word because of its high prevalence. To combat deadly diseases manufacturers are spending heavily on research and development activities in order to innovate new kinds of drugs that are more effective. By analyzing all the industrial aspects of the global market, QYR Consulting has lately published a new research report titled, “Global Paclitaxel Market Report, History and Forecast 2014-2025.”According to the report the global Paclitaxel market is predicted to expand with a healthy CAGR of 8.7% during the forecast period of 6-years, i.e. 2019-2025. The global Paclitaxel market was valued at US$90 Mn in the year 2018 and is foreseen to obtain the value of US$160 Mn by 2025 end.

Segmental Analysis

Breast cancer segment to show impressive growth in the global Paclitaxel market

The global Paclitaxel market is segmented into two segments such as by product and by application. By product, the market is further segmented into natural Paclitaxel API and semi-synthetic Paclitaxel API. Where API stands for Active Pharmaceutical Ingredient.

By application, the market is segmented into cervical cancer, ovarian cancer, breast cancer, and Others. It has been observed the increasing number of breast cancer patients across the globe and Paclitaxel is a chemotherapy medication used to treat cancer, which is projected to notice high demand during the predicted period. Various pharmaceutical companies are innovating drugs with lesser side effects and high results especially for women who are suffering from breast cancer.

North America

Regional Analysis

Rising health awareness in North America could boost the demand for Paclitaxel

North America is expected to account for a prominent share in the global Paclitaxel market. In North America, advanced technologies, rising health awareness, and expenditure towards the treatment are increasing the demand for Paclitaxel during the predicted period. Apart from North America, Asia Pacific is also anticipated to measure a heavy growth in the global Paclitaxel market because of research and development activities and the growing number of healthcare centers. 

Key Players

Some of the leading market participants operating in the global Paclitaxel market are ScinoPharm, TAPI (Teva), Southpharma, Samyang, Huiang biopharma, Hainan Yew Pharm, Yunnan Hande, Novasep, Fresenius, Jiangsu, Polymed, Phyton, and kabi. Key players are incorporating various strategies such as collaboration, mergers and acquisitions, and product differentiation in order to foothold the global market.

Global CAGR During 2020-2026


Market Dynamics

High occurrence of cancer cases to drive the global Paclitaxel market

Paclitaxel is used for the treatment of various types of cancers for positive results, this could be one of the driving factors increasing the demand for Paclitaxel in the global market. The Paclitaxel displays immediate positive results. Changing lifestyles, work pressure, unhealthy diet, and pollution are some of the elements which could higher the risk of cancer.

High incidences of cancer all over the world is foreshown to accelerate the overall market growth. Paclitaxel is easily available and there is a continuous drug development, which is likely to increase the demand for Paclitaxel in the upcoming years. However, a disproportionate injection of the drug can cause various side effects such as skin diseases, weight loss, infections, diarrhea, and several other diseases are prophesied to hamper the market growth.

For further information, check: https://www.qyrconsulting.com/reports/paclitaxel-market

Ask a Question

Get in touch with us to find answers to all your business-related queries for fast results.

   Thank you for sharing your rating with us.